Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature — François Bertucci (2022) | RDL Network
Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature
Article 2022 en
Authors
FB
François Bertucci
VN
Vincent Niziers
AN
Alexandre de Nonneville
Abstract
1 min read
ICR signature is independently associated with postoperative MFS in early-stage STS, independently from other prognostic features, including CINSARC. We built a robust prognostic clinicogenomic model integrating ICR, CINSARC, and pathological type, and suggested differential vulnerability of each prognostic group to different systemic therapies.
Javier Martín‐Broto, David S. Moura, Rafael Ramos, Luca Braglia, Paola Collini, Salvatore Lorenzo Renne, Cleofé Romagosa, Jean Michel Coindre, Valérie Velasco, Domenico Franco Merlo, Emanuela Palmerini, Silvia Stacchiotti, Vittorio Quagliuolo, Antonio López–Pousa, Giovanni Grignani, Jean Yves Blay, Antonella Brunello, Piero Picci, Paolo G. Casali, Alessandro Gronchi
Elizabeth D. Lightbody, D.R. Mani, Hasmik Keshishian, Romanos Sklavenitis-Pistofidis, Ankit K. Dutta, Esperanza Martín‐Sánchez, Elise Rees, Christine‐Ivy Liacos, Nayda Bidikian, Habib El‐Khoury, Hadley Barr, Ting Wu, Junko Tsuji, Sarah Nersesian, Nang Kham Su, Cody J. Boehner, Michael P. Agius, Michelle P. Aranha, Sabrin Tahri, Laura Hevenor, Katherine Towle, Erica Horowitz,
Discussion(0)
No comments yet. Be the first to comment.